It’s a common perception that venture investors have turned their backs—or at least hidden their pocketbooks—from big think platform-based biotechs in search of early stage funding. But a quick look at the large A rounds raised in recent years suggests that sentiment isn’t exactly true. Even as the pool of available capital shrinks and despite the gloomy exit environment, start-ups with promising technologies capable of generating multiple products across a wide swath of therapeutic areas are still gaining funding.
Ascent Therapeutics: There's Still Money in Discovery Platforms
It's a common perception that venture investors have turned their backs-or at least hidden their pocketbooks-from big think platform-based biotechs in search of early stage funding. But a quick look at the large A rounds raised in recent years suggests that sentiment isn't exactly true. Start-ups with promising technologies capable of generating multiple products across a wide swath of therapeutic areas are still gaining funding despite the dearth of capital. One example: Ascent Therapeutics.
More from Strategy
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.
• By
On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.
• By
Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.
More from Business
• By
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.
• By
Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.
• By
MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.